<DOC>
	<DOC>NCT01658826</DOC>
	<brief_summary>The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.</brief_summary>
	<brief_title>Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Adult, immunocompetent men and women in good health of any ethnic group Seropositive for Herpes Simplex Virus Type 2 (HSV2) History of recurrent episodes (&gt;=4 to &lt;=9) of genital herpes for at least 12 months Present episode of genital herpes at time of randomization Clinically relevant acute or chronic infections (excluding HSV2) Known intolerance to valacyclovir, acyclovir, or any component of the formulation Documented HSV resistance to acyclovir, valacyclovir, famciclovir or penciclovir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>AIC316</keyword>
	<keyword>Viral shedding</keyword>
</DOC>